|
Volumn 19, Issue 23, 2011, Pages 7100-7110
|
Synthesis of 6-(het) ary Xylocydine analogues and evaluating their inhibitory activities of CDK1 and CDK2 in vitro
|
Author keywords
CDK2; Inhibitory effect; Molecular docking; Purine nucleoside; Xylocydine
|
Indexed keywords
4 AMINO 6 (1H PYRROL 2 YL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (1H PYRROL 2 YL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (3 BROMOPHENYL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (3 BROMOPHENYL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (3 METHOXY) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (3 METHOXYPHENYL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (4 BROMOPHENYL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (4 BROMOPHENYL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (4 METHOXY) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (4 METHOXYPHENYL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (4 TOLYL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (4 TOLYL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (5 BROMOTHIOPHEN 2 YL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (5 BROMOTHIOPHEN 2 YL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (FURAN 2 YL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (FURAN 2 YL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 (THIOPHEN 2 YL) 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
4 AMINO 6 (THIOPHEN 2 YL) 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 [4 (TERT BUTYL)PHENYL] 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE;
4 AMINO 6 [4(TERT BUTYL)PHENYL] 5 CYANO 7 (BETA LEVO XYLOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE;
CYCLIN A2;
CYCLIN B1;
CYCLIN DEPENDENT KINASE 1;
CYCLIN DEPENDENT KINASE 1 INHIBITOR;
CYCLIN DEPENDENT KINASE 2;
CYCLIN DEPENDENT KINASE 2 INHIBITOR;
CYCLIN DEPENDENT KINASE INHIBITOR;
UNCLASSIFIED DRUG;
XYLOCYDINE DERIVATIVE;
ARTICLE;
CELL CYCLE ARREST;
CELL CYCLE G1 PHASE;
CELL CYCLE S PHASE;
CONTROLLED STUDY;
DRUG CONFORMATION;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG SYNTHESIS;
ENZYME ACTIVE SITE;
ENZYME ASSAY;
ENZYME INHIBITION;
ENZYME INHIBITOR COMPLEX;
FLOW CYTOMETRY;
HUMAN;
HUMAN CELL;
IC 50;
IN VITRO STUDY;
MOLECULAR DOCKING;
MOLECULAR MODEL;
REACTION ANALYSIS;
SIGNAL TRANSDUCTION;
CDC2 PROTEIN KINASE;
CYCLIN-DEPENDENT KINASE 2;
HELA CELLS;
HUMANS;
NUCLEOSIDES;
PURINE NUCLEOSIDES;
SIGNAL TRANSDUCTION;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 80655132884
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2011.10.003 Document Type: Article |
Times cited : (10)
|
References (44)
|